Adverse Remodeling and Pump Failure in Hearts With Pressure Overload Mediated Enhanced Catabolism of Norepinephrine Contributes to − Monoamine Oxidase

ed / Indexed Yes

[1]  M. Galinier,et al.  Genetic deletion of MAO-A promotes serotonin-dependent ventricular hypertrophy by pressure overload. , 2009, Journal of molecular and cellular cardiology.

[2]  M. Giorgio,et al.  Mitochondrial pathways for ROS formation and myocardial injury: the relevance of p66Shc and monoamine oxidase , 2009, Basic Research in Cardiology.

[3]  C. D. Wright,et al.  Nuclear α1-Adrenergic Receptors Signal Activated ERK Localization to Caveolae in Adult Cardiac Myocytes , 2008, Circulation research.

[4]  J. Shih,et al.  Monoamine oxidase inactivation: from pathophysiology to therapeutics. , 2008, Advanced drug delivery reviews.

[5]  S. Gupte,et al.  Oxidant and redox signaling in vascular oxygen sensing: implications for systemic and pulmonary hypertension. , 2008, Antioxidants & redox signaling.

[6]  James B. Mitchell,et al.  Reversal of Cardiac Hypertrophy and Fibrosis From Pressure Overload by Tetrahydrobiopterin: Efficacy of Recoupling Nitric Oxide Synthase as a Therapeutic Strategy , 2008, Circulation.

[7]  Francis G Spinale,et al.  Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. , 2007, Physiological reviews.

[8]  S. Itohara,et al.  MAO-A-induced mitogenic signaling is mediated by reactive oxygen species, MMP-2, and the sphingolipid pathway. , 2007, Free radical biology & medicine.

[9]  D. Threadgill,et al.  Cardiac response to pressure overload in 129S1/SvImJ and C57BL/6J mice: temporal- and background-dependent development of concentric left ventricular hypertrophy. , 2007, American journal of physiology. Heart and circulatory physiology.

[10]  J. Mialet-Perez,et al.  New insights on receptor-dependent and monoamine oxidase-dependent effects of serotonin in the heart , 2007, Journal of Neural Transmission.

[11]  D. Kass,et al.  Role of oxidative stress in cardiac hypertrophy and remodeling. , 2007, Hypertension.

[12]  DimitriPchejetski,et al.  Oxidative Stress–Dependent Sphingosine Kinase-1 Inhibition Mediates Monoamine Oxidase A–Associated Cardiac Cell Apoptosis , 2007 .

[13]  S. Orrenius.  Reactive Oxygen Species in Mitochondria-Mediated Cell Death , 2007, Drug metabolism reviews.

[14]  D. Bers,et al.  Calcium and cardiomyopathies. , 2007, Sub-cellular biochemistry.

[15]  F. Levy,et al.  5-hydroxytryptamine receptors in the human cardiovascular system. , 2006, Pharmacology & therapeutics.

[16]  Min Zhang,et al.  NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure. , 2006, Cardiovascular research.

[17]  P. Bernardi,et al.  Mitochondria and ischemia-reperfusion injury of the heart: fixing a hole. , 2006, Cardiovascular research.

[18]  Keith F. Tipton,et al.  The therapeutic potential of monoamine oxidase inhibitors , 2006, Nature Reviews Neuroscience.

[19]  E. Masini,et al.  Oxidative Stress by Monoamine Oxidase Mediates Receptor-Independent Cardiomyocyte Apoptosis by Serotonin and Postischemic Myocardial Injury , 2005, Circulation.

[20]  S. Minucci,et al.  Electron Transfer between Cytochrome c and p66Shc Generates Reactive Oxygen Species that Trigger Mitochondrial Apoptosis , 2005, Cell.

[21]  C. R. Wilson,et al.  Metabolic Energetics and Genetics in the Heart , 2005, Annals of the New York Academy of Sciences.

[22]  D. Kass,et al.  Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. , 2005, The Journal of clinical investigation.

[23]  D. Pimentel,et al.  A new hypertrophic mechanism of serotonin in cardiac myocytes: receptor‐independent ROS generation , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[24]  Frank J Giordano,et al.  Oxygen, oxidative stress, hypoxia, and heart failure. , 2005, The Journal of clinical investigation.

[25]  H. Mori,et al.  Extraneuronal enzymatic degradation of myocardial interstitial norepinephrine in the ischemic region. , 2004, Cardiovascular research.

[26]  K. Tipton,et al.  Monoamine oxidases: certainties and uncertainties. , 2004, Current medicinal chemistry.

[27]  D. Goldstein,et al.  Leaky Catecholamine Stores: Undue Waste or a Stress Response Coping Mechanism? , 2004, Annals of the New York Academy of Sciences.

[28]  A. Sabri,et al.  Regulation of hypertrophic and apoptotic signaling pathways by reactive oxygen species in cardiac myocytes. , 2003, Antioxidants & redox signaling.

[29]  E. Olson,et al.  Cardiac hypertrophy: the good, the bad, and the ugly. , 2003, Annual review of physiology.

[30]  D. Sorescu,et al.  Reactive oxygen species, mitochondria, and NAD(P)H oxidases in the development and progression of heart failure. , 2002, Congestive heart failure.

[31]  D. Sawyer,et al.  Role of oxidative stress in myocardial hypertrophy and failure. , 2002, Journal of molecular and cellular cardiology.

[32]  G. Eisenhofer.  The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines. , 2001, Pharmacology & therapeutics.

[33]  E. Billett,et al.  Cellular localization of monoamine oxidase A and B in human tissues outside of the central nervous system , 2001, Cell and Tissue Research.

[34]  S. Gerber,et al.  The neuronal norepinephrine transporter in experimental heart failure: evidence for a posttranscriptional downregulation. , 2001, Journal of molecular and cellular cardiology.

[35]  D. Sawyer,et al.  Reactive oxygen species mediate alpha-adrenergic receptor-stimulated hypertrophy in adult rat ventricular myocytes. , 2001, Journal of molecular and cellular cardiology.

[36]  D. Sawyer,et al.  Adrenergic overload and apoptosis in heart failure: implications for therapy. , 2000, Journal of cardiac failure.

[37]  P. Singal,et al.  Role of oxidative stress in transition of hypertrophy to heart failure. , 1996, Journal of the American College of Cardiology.

[38]  A. Quyyumi,et al.  Cardiac sympathetic nerve function in congestive heart failure. , 1996, Circulation.

[39]  A H van Gennip,et al.  Specific genetic deficiencies of the A and B isoenzymes of monoamine oxidase are characterized by distinct neurochemical and clinical phenotypes. , 1996, The Journal of clinical investigation.

[40]  J. Saffitz,et al.  Transmural heterogeneity of norepinephrine uptake in failing human hearts. , 1994, Journal of the American College of Cardiology.

[41]  J. Saura,et al.  Quantitative enzyme radioautography with 3H-Ro 41-1049 and 3H-Ro 19- 6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[42]  M. Youdim,et al.  New directions in monoamine oxidase A and B selective inhibitors and substrates. , 1991, Biochemical pharmacology.

[43]  D. Ferguson,et al.  Clinical and hemodynamic correlates of sympathetic nerve activity in normal humans and patients with heart failure: evidence from direct microneurographic recordings. , 1990, Journal of the American College of Cardiology.

[44]  S. Sakamoto,et al.  Decreased adrenergic neuronal uptake activity in experimental right heart failure. A chamber-specific contributor to beta-adrenoceptor downregulation. , 1989, The Journal of clinical investigation.

[45]  J. Javitch,et al.  Recognition sites for norepinephrine uptake: regulation by neurotransmitter. , 1983, Science.

[46]  A. Horita,et al.  Extraneuronal monoamine oxidase in rat heart: biochemical characterization and electron microscopic localization. , 1975, The Journal of pharmacology and experimental therapeutics.